Table 5 Average cost, benefit and NCBIs by age groups ($)
From: A cost-benefit analysis of mass prostate cancer screening
|  | All men | (40–49) | (50–54) | (55–69) | (70–79) | 80+ |
|---|---|---|---|---|---|---|
Benefit | Â | Â | Â | Â | Â | Â |
Average WTP-Basic information | 17.79 | 18.81 | 17.89 | 18.84 | 8.79 | 6.8 |
Average WTP-Complementary information | 16.32 | 18.54 | 12.58 | 9.68 | 7.66 | 0.53 |
Cost | Â | Â | Â | Â | Â | Â |
Average Cost- Screening by PSA | 8.65 | 8.19 | 13.16 | 12 | 22.63 | 32.41 |
Average Cost- Screening by PSA & DRE | 6.6 | 5 | 7.7 | 6.9 | 10.6 | 14 |
Nest benefit- screening by PSA | Â | Â | Â | Â | Â | Â |
Net cost-benefit index-basic information | 9.14 | 10.62 | 4.86 | 6.84 | -13.84 | -25.61 |
Net cost-benefit index- Complementary information | 7.67 | 10.35 | -0.58 | -2.32 | -14.97 | -31.88 |
Net benefit-screening by PSA & DRE | Â | Â | Â | Â | Â | Â |
Net cost-benefit index-basic information | 11.1 | 13.8 | 10.19 | 11.9 | -1.81 | -7.2 |
Net cost-benefit index- Complementary information | 9.7 | 13.5 | 4.9 | 2.78 | -2.94 | -13.47 |